Acadia Pharmaceutical has struck a collaboration deal with Tokyo-based firm Meiji Seika Kaisha to develop treatments for schizophrenia and separate neurological disorders for the Japanese market and other parts of Asia, according to a press release. San Diego-based Acadia (NASDAQ:[[ticker:ACAD]]), which has discovered a product candidate related to the deal, says it could receive up to $25 million in upfront and milestone payments from Meiji Seika Kaisha as well as royalties on potential sales. See Luke’s San Diego Biotech Survival Index, which shows that Acadia finished 2008 with $60.1 million in the bank.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
